US panel to discuss opioid studies
This article was originally published in Scrip
Executive Summary
The US FDA's anaesthetic and life support drugs advisory committee and the drug safety/risk management advisory committee will meet on 21-22 October to discuss the design of postmarket studies on two opiods. The panel will consider how Purdue Pharma's OxyContin (oxycodone hydrochloride controlled release) tablets and King Pharmaceuticals' long-acting opioid Embeda (morphine sulphate extended-release plus naltrexone hydrochloride) may reduce abuse and misuse.